Presentations 2026
Conference on Retrovirus and Opportunistic Infections (CROI 2026), Denver, Colorado, USA, 22-25 February 2026
Poster presentation:
Evaluating the impact of integrase inhibitors (INSTIs) on cardiovascular disease (CVD) presented by Bastian Neesgaard on behalf of the RESPOND study group. POSTER
International Workshop on HIV and Hepatitis Observational Databases, Thessaloniki, Greece, 26-29 March 2026
Poster presentation:
Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium, presented by Bastian Neesgaard on behalf of the RESPOND study group
World Hepatitis Summit 2026, Bangkok, Thailand, 28-30 April 2026
Poster presentation:
European practical implementation guidance for bloodborne virus opt-out testing in emergency departments presented by Dorthe Raben on behalf of the EuroTEST Steering Committee. POSTER
AIDS 2026, the 26th International AIDS Conference, Rio de Janeiro, Brazil, 26-31 July 2026
Poster presentations:
Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium presented by Bastian Neesgaard on behalf of the RESPOND study group. POSTER
Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration presented by Lauren Greenberg on behalf of the RESPOND study group. POSTER
European Society of Cardiology Congress 2026, Munich, Germany, 28-31 August 2026
Poster presentation:
Sex disparities of myocardial infarction in individuals with HIV across Europe and Australia: a multinational cohort study presented by Nadine Jaschinski on behalf of the RESPOND study group. POSTER
HIV Drug Therapy Glasgow 2026, Glasgow, Great Britain, 8-11 November 2026
Poster presentation:
Antiretroviral therapy use in ageing people with HIV: RESPOND cohort study, led by Olof Elvstam et al.
Capturing mortality among people living with HIV across Europe: a comparison of routine surveillance data with an international cohort study, led by Bastian Neesgaard et al.
Oral presentation:
Treatment uptake, and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy vs dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV cohort collaboration, led by Alisa Timiryasova et al.